Title : Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Pub. Date : 2021

PMID : 34616492






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: In patients with newly diagnosed ovarian cancer, bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination, have shown benefit as maintenance treatment following platinum-based chemotherapy. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens
2 Background: In patients with newly diagnosed ovarian cancer, bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination, have shown benefit as maintenance treatment following platinum-based chemotherapy. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens